Samsung Biologics launches organoid platform to boost early-stage drug discovery

South Korea's leading contract development and manufacturing organization, Samsung Biologics, announced Monday the launch of Samsung Organoids, a cutting-edge drug screening service designed to support corporate clients throughout drug discovery and development.
Organoids are three-dimensional cell culture systems engineered to closely replicate the structure and function of human organs. Due to their high physiological relevance, organoids are rapidly emerging as a next-generation research model in drug development. They offer clinically meaningful insights into drug responses, making them valuable tools for lead compound selection, biomarker discovery and efficacy prediction.
'The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,' said John Rim, CEO and president of Samsung Biologics.
'The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.'
Samsung Organoids will enable precision screening to predict patient-specific drug responses, streamline preclinical development and accelerate timelines for investigational new drug filings. The platform uses data-driven analysis to assess the characteristics and mechanisms of drug candidates, offering multi-modal insights that enhance decision-making.
Through the expansion, Samsung Biologics broadens its service portfolio to include preclinical research, covering the full spectrum from target discovery and lead identification to preclinical studies and clinical trial planning. By leveraging its expertise in drug development and manufacturing, the company aims to help clients overcome early-stage development hurdles and improve clinical outcomes.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Korea Herald

3 hours ago

• Korea Herald

Seoul shares snap 5-day rally following US strike on Iran; won at 1-month low

South Korean stocks ended lower Monday to snap a five-day winning streak, over heightened Middle Eastern uncertainties following the United States' bombing attacks on key Iranian nuclear facilities over the weekend. The local currency was trading sharply lower against the US dollar. The benchmark Korea Composite Stock Price Index slid 7.37 points, or 0.24 percent, to close at 3,014.47, after dipping to an intraday low of 2,971.36. Trade volume was heavy at 619.8.7 million shares worth 17.76 trillion won ($12.8 billion), with losers outnumbering winners 646 to 265. Foreigners and institutions combined sold local shares worth 1.32 trillion won, while retail investors snapped up shares worth 1.4 trillion won. On Friday, the Kospi topped the 3,000-point mark for the first time in more than three years, backed by investor optimism over policies under the Lee Jae Myung administration. But investor sentiment was dampened by heightened tensions in the Middle East over the weekend. The US used B-2 bombers to launch air strikes on three key nuclear sites in Iran on Saturday, with President Donald Trump describing the operation as "successful" and claiming the Iranian sites were "obliterated." Chip and bio shares led the overall losses, with market heavyweight Samsung Electronics dropping 2.52 percent to 58,000 won and Samsung Biologics slumping 2.36 percent to 992,000 won. Battery and heavy machinery shares also retreated, with top battery manufacturer LG Energy Solution down 3.61 percent to 294,000 won and defense systems giant Hanwha Aerospace dropping 2.03 percent to 919,000 won. Automotive and shipbuilders also lost ground. Top automaker Hyundai Motor plunged 4.05 percent to 201,500 won, and leading shipyard HD Hyundai Heavy Industries slid 2.14 percent to 433,500 won. In contrast, internet-related shares and financial companies advanced. Top portal operator Naver soared 7.61 percent to 290,000 won, and KB Financial climbed 1.03 percent to 107,600 won. The local currency was trading at 1,384.3 won against the greenback at 3:30 p.m., down sharply by 18.7 won from the previous session, and marking the lowest since May 21, when the corresponding reading was 1,387.2. (Yonhap)

Korea Herald

9 hours ago

• Korea Herald

Seoul shares open over 1% lower following US strike on Iran

South Korean stocks opened over 1 percent lower Monday over heightened Middle Eastern uncertainties following the United States' bombing attacks on key Iranian nuclear facilities over the weekend. The benchmark Korea Composite Stock Price Index dropped 38.17 points, or 1.26 percent, to 2,983.67 in the first 15 minutes of trading. Engaging itself in the Israel-Iran conflict, the US used B-2 bombers to launch air strikes on three key nuclear sites in Iran on Saturday, with President Donald Trump describing the operation as "successful" and claiming the Iranian sites were "obliterated." Most blue chips lost ground, with market heavyweight Samsung Electronics plunging 2.61 percent and chip rival SK hynix sliding 2.53 percent. Top bio company Samsung Biologics dropped 1.77 percent, and leading battery manufacturer LG Energy Solution plummeted 3.61 percent. Top automaker Hyundai Motor retreated 4.05 percent. In contrast, refiners and internet portal operators advanced. Leading refiner SK Innovation jumped 3.71 percent, and top internet portal firm Naver gained 1.86 percent. The local currency was trading at 1,379.3 won against the greenback at 9:15 a.m., down sharply by 13.7 won from the previous session. (Yonhap)

Korea Herald

4 days ago

• Korea Herald

[Bio USA] Samsung Biologics expands strategic focus to top 40 global pharma

BOSTON — Samsung Biologics announced plans Wednesday to further broaden its customer base, aiming to serve the world's top 40 pharmaceutical companies up from the current top 20. "Today, we serve more than 130 clients, including 17 of the world's top 20 pharmaceutical companies, with a batch success rate exceeding 99 percent and 359 regulatory approvals from global health authorities," said Kevin Sharp, executive vice president and head of sales and operations at Samsung Biologics, during a press conference held on the sidelines of Bio USA. Samsung Biologics has been establishing local offices in strategic regions and maintaining seamless collaboration with its global headquarters in Songdo. 'We already operate sales offices in New Jersey and Boston through our US subsidiary, and opened a new office in Tokyo earlier this year to better contact the top 40 pharma companies." Samsung Biologics has also built core competencies in advanced and emerging modalities — including messenger mRNA, antibody drug conjugates and competetive genetic therapies. Looking ahead, the company plans to begin manufacturing ADC drug products and pre-filled syringes by 2027. Further expanding its value chain integration, Samsung Biologics is now moving upstream into contract research services. This includes the launch of its first organoid-based drug screening platform, Samsung Organoids, a move that marks its formal entry into contract research. At a related press briefing on Tuesday, Lee Sang-myung, vice president and head of Business Strategy at Samsung Biologics, emphasized the promise of organoid technology in revolutionizing drug development. 'Organoids are rapidly transforming the drug development landscape,' he said. 'With up to 85 percent physiological similarity to human patients, they provide a more accurate, scalable and cost-effective alternative to traditional animal testing.' According to market intelligence firm Research and Markets and others, the global patient-derived organoid market is valued at $1 billion in 2024 and is projected to grow to $3.3 billion by 2030, with a compound annual growth rate of 22 percent. Such rapid growth is being driven in part by the FDA's push to reduce reliance on animal testing and to promote ethically sound alternatives. Samsung Biologics' organoid strategy is further bolstered by an exclusive partnership with Samsung Medical Center, recently ranked No. 3 globally in cancer care by Newsweek in 2025. The collaboration merges SMC's vast clinical dataset drawn from over 4.5 million patients, with Samsung Biologics' capabilities in manufacturing and data analytics, enabling the generation of highly precise drug efficacy data. 'The launch of Samsung Organoids marks a strategic inflection point for us,' Lee noted. 'Having evolved from a pure CMO in 2011 to a CDO in 2018, we are now transitioning into a fully integrated CRDMO — adding research and discovery to our core manufacturing strengths.'